1996
DOI: 10.1016/s0039-6257(96)82028-5
|View full text |Cite
|
Sign up to set email alerts
|

Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: A review of safety, efficacy, dose response, and dosing studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
57
0
2

Year Published

1998
1998
2016
2016

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 117 publications
(59 citation statements)
references
References 17 publications
0
57
0
2
Order By: Relevance
“…It reduces the IOP at the 0800 trough level approximately 15-16% from baseline. [11][12][13][14] It is labelled three times a day, but is most frequently dosed twice daily. Brimonidine may cause side effects, including ocular allergy with an incidence approximately 10% presenting 3 months or later after initiation of therapy.…”
Section: Discussionmentioning
confidence: 99%
“…It reduces the IOP at the 0800 trough level approximately 15-16% from baseline. [11][12][13][14] It is labelled three times a day, but is most frequently dosed twice daily. Brimonidine may cause side effects, including ocular allergy with an incidence approximately 10% presenting 3 months or later after initiation of therapy.…”
Section: Discussionmentioning
confidence: 99%
“…Desde o início do uso em 1996 da solução oftalmológica de tar tarato de brimonidina 0,2% (Alphagan ® ; Allergan, Irvine, CA), este agonista adrenérgico seletivo alfa2 provou ser um efetivo e seguro agente para controle a longo prazo do glaucoma e da hipertensão ocular (1,2) . O mecanismo pelo qual esta droga reduz a pressão in traocular (PIO) é principalmente pela diminuição da produção de humor aquoso e em menor importância pelo aumento da drenagem uveoescleral (2,3) .…”
Section: Introductionunclassified
“…O mecanismo pelo qual esta droga reduz a pressão in traocular (PIO) é principalmente pela diminuição da produção de humor aquoso e em menor importância pelo aumento da drenagem uveoescleral (2,3) . Sua eficácia quando usada duas vezes ao dia é com parada à do maleato de timolol 0,5%, sendo considerada uma efetiva opção para monoterapia, terapia adjuvante e de substituição (46) .…”
Section: Introductionunclassified
“…1 Clinical trials have proved it to be an effective drug for treating chronically elevated IOP and the prophylactic treatment of acute pressure rises. 2 Its hypotensive action is primarily attributed to aqueous suppression, though an uveoscleral outflow has also been suggested. 3 Its longterm efficacy in lowering intraocular pressure is comparable to that of timolol eye drops 4 but without the adverse cardiopulmonary side effects associated with the latter.…”
Section: Introductionmentioning
confidence: 99%
“…2 These include dryness of the mouth, fatiguedrowsiness, headache and an allergic reaction. 4 Apart from ocular allergy the above adverse events are not statistically different from those patents on beta blockers.…”
Section: Introductionmentioning
confidence: 99%